`
`Page 1
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` ________________________________________
`
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` ________________________________________
`
` MYLAN PHARMACEUTICALS INC., et al.,
`
` Petitioner,
`
` v.
`
` MERCK SHARP & DOHME CORP.,
`
` Patent Owner.
`
` __________________________________________
`
` Case IPR2020-00040
` Patent No. 7,326,708 B2
`
` __________________________________________
`
` DEPOSITION OF GARY HERMAN, M.D.
`
` APPEARING REMOTELY
`
` October 26, 2020
`
` 1:02 p.m.
`
`Reported by
`
`Rebecca J. Callow, RMR, CRR, RPR, CSR
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 001
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 2
`
` REMOTE APPEARANCES
`
`ON BEHALF OF MYLAN PHARMACEUTICALS, INC.:
`
` Katten Muchin Rosenman LLP
`
` 550 South Tryon Street
`
` Suite 2900
`
` Charlotte, North Carolina 28202
`
` 704-344-3185
`
` By: Lance Soderstrom
`
` lance.soderstrom@katten.com
`
` Jitendra Malik, Ph.D.,
`
` jitty.malik@katten.com
`
`ON BEHALF OF MERCK:
`
` Williams & Connolly LLP
`
` 725 Twelfth Street, Northwest
`
` Washington, D.C. 20005
`
` 202-434-5000
`
` By: Alexander S. Zolan
`
` azolan@wc.com
`
` Sahobo Zhu
`
` szhu@wc.com
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 002
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 3
`
` REMOTE APPEARANCES (CONTINUED)
`
`ON BEHALF OF FOR DR. REDDY'S LABORATORIES, INC.,
`
`DR. REDDY'S LABORATORIES, LTD.:
`
` Lerner David Littenberg Krumholz & Mentlik
`
` 20 Commerce Drive
`
` Cranford, New Jersey 07016
`
` (908) 654-5000
`
` By: Russell W. Faegenburg
`
` rfaegenburg@lernerdavid.com
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 003
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 4
`
` I N D E X
`
` PAGE
`
`GARY HERMAN, M.D.
`
`Examination by Mr. Soderstrom .....................6
`
`Examination by Mr. Zolan .........................39
`
`Court Reporter's Certificate .....................45
`
`Signature page ...................................48
`
`Errata ...........................................50
`
` * * * * *
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 004
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 5
`
` E X H I B I T S
`
`NO. DESCRIPTION PAGE
`
` (None offered.)
`
` * * * * *
`
`1
`
`2 3
`
`4
`
`5 6 7
`
`8 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 005
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 6
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Tuesday, October 26, 2020, 1:02 p.m.
`
` P R O C E E D I N G S
`
` - - - - -
`
` GARY HERMAN, M.D.,
`
` called as a witness herein, having
`
` been first duly sworn by a Notary Public,
`
` was examined and testified as follows:
`
` EXAMINATION
`
` BY MR. SODERSTROM:
`
` Q. Good afternoon, Dr. Herman.
`
` A. Hello.
`
` Q. Can you, please, state your full name for
`
`the record?
`
` A. Gary Alan Herman.
`
` Q. And we're in different times here, but just
`
`because I can't be there, do you have any documents
`
`that are in front of you?
`
` A. I do.
`
` I have the binder that is labeled
`
`"Herman IPR Depo Prep." And I'm in my home office,
`
`so my wife's got some papers around that are
`
`irrelevant.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 006
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 7
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. I can promise you I won't ask you about
`
`those.
`
` But in terms of the binder that you do
`
`have in front of you, can you just let me know what
`
`documents you have in there?
`
` A. Okay. I have document 2109, my
`
`declaration; 1001, the patent, the '708; 2106, the
`
`protocol 005, the clinical study report; 2107,
`
`protocol 6, the clinical study report; 2108, the
`
`batch analysis module from the NDA.
`
` 2110, the summary of the product
`
`development team for DPP-IV; 2111, draft preliminary
`
`interim analysis email; 2112, the Demuth 2000
`
`article. 2113, the Popisilik 2002 article; 2114 is
`
`the Thornberry 2007 article; 2115 is the Rothenberg
`
`2000 abstract; and 2158 is the DPP-IV background
`
`that is an email from me. And --
`
` Q. And is it fair -- yes. Sorry.
`
` A. And I have not written in this binder at
`
`all.
`
` Q. You at least guessed one of my question to
`
`come.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 007
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` The other one I had for you was, are
`
`there any documents other than those that are in your
`
`binder that you considered in putting together your
`
`declaration in this matter?
`
` A. No.
`
` Q. And just to keep things clean, and to help
`
`me, do you mind refraining from accessing or
`
`consulting certain of those materials unless I'm
`
`specifically asking you a question on that document?
`
` Or, to the extent that you need to
`
`reference another document, if you'd just let me know
`
`which one you're looking at as we go through the
`
`questions.
`
` A. Sure.
`
` Q. I'm going to go through and ask you a
`
`series of questions today. I'd ask that you answer
`
`fully and truthfully.
`
` Is there anything that would prevent
`
`you from doing so today?
`
` A. No.
`
` Q. You understand that you're under oath?
`
` A. Yes, I do.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 008
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 9
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. If you don't understand a question, please,
`
`just let me know, I'll do my best to rephrase it.
`
`If you need a break, please also let me know.
`
` I know you are a busy man and I'm going
`
`to do everything in my power to get you out of here
`
`in fairly short order.
`
` A. Thank you.
`
` Q. Have you been deposed before?
`
` A. I've not been deposed before.
`
` I have been a witness testifying in a
`
`trial in a child abuse case when I was a practicing
`
`physician.
`
` Q. And, just roughly, how long ago was that?
`
` A. It would have been around 1994.
`
` Q. Are you being compensated for your time
`
`here today?
`
` A. I am not.
`
` Q. What did you do, to the extent that you did
`
`anything, in preparing for today's deposition?
`
` MR. ZOLAN: Dr. Herman, let me just
`
`remind you not to reveal the contents of any
`
`communications that you and I have had. But,
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 009
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 10
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`otherwise, go ahead and answer the question.
`
` A. I have had conversations with Alex. I have
`
`reviewed all of the documents that were provided,
`
`and I collaborated on the drafting of the
`
`declaration.
`
` BY MR. SODERSTROM:
`
` Q. And, roughly, how long did you spend
`
`meeting or speaking with Alex?
`
` A. Maybe a total of ten hours, something like
`
`that.
`
` Q. Have you spoken with any other
`
`individual -- or let me rephrase that.
`
` Have you spoken with any individuals at
`
`Merck in preparing for this deposition?
`
` A. I have not spoken to any individuals other
`
`than -- other than Alex and his team.
`
` Q. When did Alex or someone from his team
`
`first contact you in connection with this matter?
`
` A. I can't remember exactly. This year feels
`
`like ten years.
`
` I was first approached through the
`
`assistant general counsel, I think it was, in
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 010
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 11
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`August, something like that. But I could be wrong
`
`about that.
`
` Q. If I've done this correctly, I've uploaded
`
`a document that you're able to download. I assume
`
`it's the same as what you have in your binder as
`
`Merck Exhibit 2109.
`
` But if you're able to just download it
`
`and confirm it so that I know that we're looking at
`
`the same document, I'd appreciate that.
`
` A. How do I do that?
`
` Q. I think if you're able to click on the
`
`chat -- there should be a chat option when you hit
`
`"More" at the bottom of your screen, possibly?
`
` A. Oh, okay.
`
` Q. And then in the chat, you'll see,
`
`hopefully, something titled EX2109 and the option to
`
`download.
`
` A. Yes. It's downloading.
`
` (Pause in proceedings.)
`
` A. What I'm looking at, it says -- okay. Yes.
`
`This is the -- this is the same document.
`
`\\\
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 011
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 12
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` BY MR. SODERSTROM:
`
` Q. Okay. And this is your declaration that
`
`was submitted with --
`
` A. Right.
`
` Q. Okay.
`
` A. So do you want me to be looking at this or
`
`the hard copy of it? It's a little bit easier for
`
`me to look at the hard copy.
`
` Q. Whatever you're comfortable with,
`
`Dr. Herman, is fine. I just wanted to make sure
`
`that what I have here is the same as what you have.
`
`I don't doubt that it is, but I just want to --
`
` A. Okay. So it's okay for me to close this
`
`out now then.
`
` Q. That's fine.
`
` A. Okay.
`
` Q. I just want to confirm, on page 11 of that
`
`is your signature?
`
` A. This is my signature on page 11.
`
` Q. I believe you noted earlier that you worked
`
`in collaboration in drafting this declaration.
`
` Were there certain parts that you
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 012
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`drafted and others that were drafted by others?
`
` A. So in the drafting of the declaration, I
`
`had conversations. Someone else wrote the words on
`
`here. I reviewed carefully every word and signed
`
`the document.
`
` Q. Did you select the documents that are
`
`referenced in your declaration?
`
` A. I did not select the documents. It was not
`
`my choice which documents weren't in here.
`
` Q. And prior to someone reaching out to you
`
`regarding this declaration, when was the last time
`
`that you would have seen the documents that are
`
`cited in your declaration?
`
` A. Some of these documents I have never seen.
`
` The last time would have been the two
`
`clinical study reports, protocol 5 and protocol 6,
`
`which would have been in early 2006.
`
` Q. And can you just identify which documents
`
`you're referring to that you had never seen?
`
` A. I never saw the patent, 1001. And I had
`
`never seen 2108, the batch analysis. And I had
`
`never seen the -- 2110, the email there. And let me
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 013
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 14
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`just make sure.
`
` I believe I have seen the remaining
`
`documents prior.
`
` Q. Have you seen anybody else's declaration
`
`that has been submitted in connection with this
`
`matter?
`
` A. I have not seen anybody else's declaration.
`
` Q. And with respect to your declaration, are
`
`there any corrections or changes that you would like
`
`to make, having reviewed it again more recently?
`
` A. I have reviewed all of the declaration and
`
`have signed off because I attest that this is true
`
`and accurate.
`
` Q. And that's fair. And I won't get bogged
`
`down in this, but my question is just to ensure
`
`that, when you signed it -- between when you signed
`
`it on August 19th, 2020, and sitting here today,
`
`that there aren't any changes that you would like to
`
`make to the declaration, or corrections or anything
`
`of the sort?
`
` A. Not at this time.
`
` Q. And your declaration was meant to be a
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 014
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`complete statement for issues that you are offering
`
`testimony on. Is that correct?
`
` A. This is intended to be a complete
`
`statement.
`
` Q. And if you turn to page 2 of your
`
`declaration, you reference Claim 17, and then in
`
`paragraph 3, you reference Claim 19 of the
`
`'708 patent.
`
` I think you said earlier that you
`
`hadn't seen the patent before, but in preparing this,
`
`did you look at any other claims of the '708 patent?
`
` A. In preparation, to understand -- fully
`
`understand the context, I read the document from
`
`beginning to end of the '708. But I will say that
`
`the first time I read it, I'm not an author. I
`
`would consider myself an extreme novice in IP.
`
` Q. Did you find it exciting?
`
` A. I did not.
`
` Q. Is it fair to say, though, that, sitting
`
`here today, your testimony is limited to these two
`
`claims?
`
` A. I think that's a fair statement.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 015
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 16
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. And is it fair to say that -- well, let me
`
`ask you.
`
` Do you have any experience in salt
`
`formation?
`
` A. I'm not a chemist. I sat on teams where my
`
`colleagues were responsible for delivering those.
`
`But, you know, again, I would say I know enough to
`
`ask somebody questions, like "why is that good," but
`
`I would, again, consider myself an extreme novice in
`
`this.
`
` Q. And I suppose -- a slightly related
`
`question -- then, would you consider yourself a
`
`novice in process chemistry?
`
` A. I would answer that very similarly. I had
`
`colleagues; that was part of the deliverable. They
`
`needed to deliver a good amount of suitable drug
`
`that we could test in the clinic.
`
` Q. But in terms of your personal experience,
`
`you would agree with me that you have no personal
`
`experience in process chemistry. Is that fair?
`
` A. That is correct.
`
` Q. And is it also fair that -- again, limited
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 016
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 17
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`to personal experience, that you have no personal
`
`experience in formulation?
`
` A. That is correct.
`
` Q. Looking back at those two claims that are
`
`referenced in paragraphs 2 and 3 of your
`
`declaration, they both use the phrase
`
`"therapeutically effective." Do you see that?
`
` And what does that mean to you?
`
` MR. ZOLAN: Object to form.
`
` A. Could you be more precise in what it is
`
`that you're looking for in your question?
`
` BY MR. SODERSTROM:
`
` Q. Sure.
`
` I'm just looking at paragraphs 2 and 3
`
`of your declaration. And you use the words
`
`"therapeutically effective" in each paragraph. I'm
`
`just trying to understand what that means to you.
`
` MR. ZOLAN: Object to form.
`
` Go ahead.
`
` THE WITNESS: Should I answer?
`
` MR. ZOLAN: Yes. Yeah. The
`
`objections are for the record. But go ahead and
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 017
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 18
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`answer.
`
` THE WITNESS: Okay.
`
` A. Again, with the understanding that I'm
`
`not -- you know, I'm a novice in looking at patents.
`
` What it means to me, okay, is that the
`
`composition is going to have a benefit clinically,
`
`meaningful beneficial effect, in the disease in
`
`question; in this case, type 2 diabetes.
`
` BY MR. SODERSTROM:
`
` Q. Okay. Is that -- is it fair -- or I
`
`suppose, correct me if I'm going too far with it.
`
` But to you -- and, again, I realize
`
`that you -- you don't spend a lot of time creating
`
`patents.
`
` But for "therapeutically effective," is
`
`it eliciting some response based on taking a
`
`particular drug?
`
` MR. ZOLAN: Object to form.
`
` A. I'm not sure what it is that you're looking
`
`for.
`
` Clearly, it is -- it references
`
`amount. And so there -- it has a drug concentration
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 018
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 19
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`and a dose that matter. It's not like you can just
`
`give any amount. But beyond that, I'm not really
`
`sure what you're looking for from me.
`
` BY MR. SODERSTROM:
`
` Q. And I appreciate that. And to be fair,
`
`you'll see this. You are undoubtedly far smarter
`
`and I. And it will be rare that I am looking for
`
`something in particular, other than to get your
`
`thoughts on any of these questions that I have here
`
`today. But I do appreciate that.
`
` If you look down at paragraph 4 in your
`
`declaration, do you see it says, "I did not invent
`
`the subject matter claimed in the '708 patent."
`
` Do you see that?
`
` A. Yes.
`
` Q. And, again, I'm just curious as to what you
`
`mean by that.
`
` A. I'm just rereading paragraph 4, because I
`
`want to make sure that I'm complete here.
`
` Q. By all means. Take your time and review
`
`anything that you need to.
`
` (Document review.)
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 019
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 20
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. So as I stated, I -- I was not involved in
`
`the drafting or authorship of the patent. I was not
`
`responsible for the determination of the salt form,
`
`nor the formulation; but I was the clinical team
`
`lead -- well, actually, it was the product team
`
`lead, what we called a PDT, and was the physician
`
`responsible for the design and oversight and
`
`drafting of the studies that are relevant to this.
`
` And I was there at the time that these
`
`things happened, and so I can talk -- I can speak to
`
`when these things happened and what's in those
`
`studies.
`
` BY MR. SODERSTROM:
`
` Q. And so for -- when you're referring to
`
`those studies and the relevant -- I think you said
`
`relevant aspect of it, you're talking about
`
`Claims 17 and 19 of the patent that you have
`
`pertinent information on. Is that correct?
`
` A. I am speaking about the clinical studies
`
`that I was responsible for, yes.
`
` Q. And the subject matter of Claim 17 and
`
`Claim 19, again, you refer to those in paragraphs 2
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 020
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 21
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`and 3 in your declaration.
`
` Who were the inventors responsible for
`
`that particular subject matter?
`
` A. I'm going to just open up and make sure
`
`that -- can I just pull out Claim 17? Is that okay
`
`with you?
`
` Q. Of course.
`
` A. I don't know any of the inventors. I
`
`didn't recollect any of their names.
`
` My understanding, though, is that they
`
`were in the process research and pharmaceutical
`
`research and development organizations. And more
`
`senior individuals that they would have been working
`
`with were on the team that I cochaired. The DPP-IV
`
`product development team.
`
` Q. If you go back to your declaration, in
`
`paragraph 12, there you reference protocol 005. And
`
`I think you mentioned that earlier today in your
`
`testimony as well.
`
` Do you see that in paragraph 12?
`
` A. I'm looking at paragraph 12.
`
` Q. And do you see the reference to
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 021
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 22
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`protocol 005 there?
`
` A. I do see the reference to protocol 005.
`
` Q. I'm going to try to do this again, and
`
`bother you with this for one second just to try to
`
`download the exhibit that I have, hopefully,
`
`uploaded into the chat.
`
` And I understand you may have the paper
`
`copy in front of you. I don't necessarily need you,
`
`unless you feel the need, to go through each page to
`
`confirm that what I have just uploaded is the same as
`
`what you have in front of you.
`
` But I would like to ask you a few
`
`questions about this document. And so if you'd
`
`prefer to use the paper copies in front of you, I'll
`
`just ask that you confirm that it's the same as what
`
`I have uploaded in the chat.
`
` A. Okay. I have protocol 005, Clinical Study
`
`Report, in front of me and it's downloading now.
`
`And I'll let you know when it completes.
`
` Q. Okay. Thank you.
`
` (Document review.)
`
` A. Okay. This is the same document.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 022
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 23
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` BY MR. SODERSTROM:
`
` Q. And is it correct that you are one of the
`
`authors of this report. Is that right?
`
` A. I was the principal author on this clinical
`
`study report.
`
` Q. And this is a true and correct copy of
`
`protocol 005, as far as you can tell?
`
` A. The document appears to be a true and
`
`correct copy.
`
` Q. On page 17 of that protocol, do you see
`
`where it says "Primary Therapy Period," sort of like
`
`the fourth main row under "Synopsis."
`
` Do you see that?
`
` A. I'm right there at the period of 14th
`
`October 2002 to 16th of March. Yeah. I see that.
`
` Q. And then just after what you read, it says
`
`the frozen file date was December 3rd, 2003.
`
` What's the frozen file date?
`
` A. So the frozen file date is the penultimate
`
`step before the data is locked and analyzed.
`
` So any data cleaning or any
`
`reconciliation -- so there was a lot of sampling,
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 023
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 24
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`pharmacokinetics, et cetera. Any questions that
`
`anybody wanted to ask verifying, say, did that
`
`sample really get taken at 9 a.m., or was it
`
`9:05 a.m. Those can happen. But once it's locked,
`
`that's it. Or once it's frozen, that's it.
`
` Q. And so, I suppose, just what happens during
`
`that period of -- we have the primary therapy period
`
`that's ending March 16th, 2003.
`
` What happens between that date and --
`
`and the frozen file date being selected or enforced
`
`or executed?
`
` A. Once the last patient has finished their
`
`visit, which would have been 16th of March 2003, the
`
`clinical team has an opportunity to go back and
`
`review all of the source documentation, the data,
`
`where it came from, because it all has to be
`
`reconstructed after the fact, and to make sure that
`
`it looks perfect.
`
` And if something looks -- if there's
`
`any question about anything in the dataset, that
`
`they have an opportunity to go back and ask the
`
`study side's investigator, please verify this date,
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 024
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 25
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`before they actually run the final analysis.
`
` Q. If you would turn to page 26 of that same
`
`protocol.
`
` A. I'm on page 26.
`
` Q. Yeah. Hopefully, you're seeing a title,
`
`"Rationale for the Present Study," at the top. Is
`
`that right?
`
` A. I do see that.
`
` Q. At the end of the third paragraph there, it
`
`looks like it is one somewhat long sentence that
`
`reads:
`
` "One or both doses of MK-0431 were
`
`hypothesized to reduce post-OGTT glucose by at least
`
`10 percent as compared to placebo.
`
` "The rationale for this target was
`
`based on the observation that other oral
`
`antihyperglycemic agents that target post-prandial
`
`glucose" -- I won't be able to pronounce these next
`
`couple words, so I'll rely on you for that one to the
`
`extent we need it -- "achieve reductions of at least
`
`10 percent or greater."
`
` Can you just explain to me what those
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 025
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 26
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`two sentences mean?
`
` A. First off, I apologize for my lengthy
`
`prose.
`
` At the beginning, we had to decide and
`
`reason what a clinically meaningful, therapeutically
`
`effective amount of glucose lowering following a
`
`glucose tolerance test would be.
`
` And OGTT is -- you ask somebody to
`
`drink glucose, their glucose goes up, you measure
`
`the reduction by your treatment.
`
` And we looked at examples of other
`
`agents that did this that were meaningful and led to
`
`beneficial outcomes. And those all had at least a
`
`10 percent or greater effect. That's where that
`
`came from.
`
` And so we were looking for at least a
`
`10 percent reduction in glucose excursion following
`
`this test in the presence of MK-0431.
`
` Q. And then on the next page, sort of, I
`
`suppose, in the conclusory paragraph, or at least
`
`the last paragraph of this section, it says:
`
` "In order to corroborate estimates
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 026
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 27
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`(based on preclinical data) of the relationship
`
`between near-maximum glucose lowering and MK-0431
`
`plasma concentrations, plasma DPP-IV activity and
`
`augmentation of active GLP-1 levels, preliminary
`
`information on the PK/PD relationship of MK-0431 was
`
`also sought."
`
` And, again, I'm just hoping that you
`
`can explain to me what is meant by this sentence.
`
` A. So there's an interrelationship between
`
`giving the drug, inhibiting the DPP-IV enzyme. And
`
`the DPP-IV enzyme normally cleaves these incretin
`
`hormones. GLP-1 being the key one.
`
` And so it stabilizes and prevents the
`
`degradation, meaning augmentation of active GIP to
`
`prevent degradation between more GLP-1 that's
`
`uncleaved.
`
` And by putting together the
`
`interrelationship between drug concentration, how
`
`much we're inhibiting the enzyme, how much we're
`
`stabilizing the GLP-1, and looking at relationship
`
`between that and glucose lowering, we believed, at
`
`the time that we wrote this, that we would be able
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 027
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 28
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`to predict those that would work over long-term
`
`trials.
`
` And we intended to go directly from
`
`this trial into a large Phase IIb dose-ranging
`
`finding study, which is what was written there in
`
`the document. And that is, in fact, what happened.
`
` Q. And so just turning back to sort of the
`
`beginning of that sentence where it's corroborating
`
`estimates based on preclinical data, can you just
`
`let me know sort of how that process works?
`
` A. Well, there were --
`
` MR. ZOLAN: Objection to form.
`
` A. There were preclinical models, in this case
`
`rodents, that went through all these same things.
`
`And we have initial estimates of how much inhibition
`
`of the enzyme, how much augmentation we give to the
`
`glucose lowering. And that's what guided the sample
`
`size here, and what we'd been looking for initially.
`
` BY MR. SODERSTROM:
`
` Q. If you would turn to page 155 of that same
`
`protocol.
`
` A. I'm looking at page 155.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 028
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 29
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. Okay. And just under the point 9
`
`"Discussion," it opens up by saying, "DPP-IV
`
`inhibitors are expected to promote efficacy in
`
`glycemic control in patients with type 2 diabetes by
`
`inhibiting the degradation of the incretin hormones
`
`GLP-1 and GIP" -- and in possibly others -- "thereby
`
`stabilizing the active intact form of the hormones
`
`to enhance incretin action."
`
` And so, I guess, my question is
`
`twofold. Is this sort of what you were just
`
`explaining to me or is this something slightly
`
`different?
`
` A. I believe you could have read this section
`
`and then you wouldn't have had to ask me the
`
`question.
`
` Q. Well, that's fair. But luckily for you,
`
`and I suppose for me, is I still get to ask the
`
`questions and we can see where it goes. Let me
`
`rephrase it then, based on that.
`
` Why was it expected?
`
` A. Why was what expected?
`
` Q. I'm sorry.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Mylan (IPR2020-00040) Ex. 1023 p. 029
`
`
`
`Gary Herman, M.D. - October 26, 2020
`
`Page 30
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` That DPP-IV inhibitors are expected to
`
`promote efficacy in glycemic control in patients with
`
`type 2 diabetes?
`
` Is it strictly what follows?
`
` A. This is a weight-of-evidence argument. And
`
`it was a hypothesis at the time that we started down
`
`this track that turned out to be true.
`
` There was preclinical data for a
`
`couple of other molecules that had been in the
`
`clinic that also showed that the hypothesis was
`
`likely to be true, which showed glucose lowering in
`
`the clinic. And our job was to nail it. But at the
`
`time that we started this, I would sa